Intech Investment Management LLC Has $706,000 Stake in InMode Ltd. (NASDAQ:INMD)

Intech Investment Management LLC lifted its stake in InMode Ltd. (NASDAQ:INMD) by 36.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 42,300 shares of the healthcare company’s stock after purchasing an additional 11,260 shares during the period. Intech Investment Management LLC owned 0.06% of InMode worth $706,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of INMD. Systematic Financial Management LP boosted its position in InMode by 13.3% in the 3rd quarter. Systematic Financial Management LP now owns 982,111 shares of the healthcare company’s stock valued at $16,647,000 after buying an additional 115,492 shares during the last quarter. Barclays PLC lifted its stake in shares of InMode by 113.5% during the third quarter. Barclays PLC now owns 169,630 shares of the healthcare company’s stock valued at $2,876,000 after acquiring an additional 90,173 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of InMode by 54.1% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,480 shares of the healthcare company’s stock valued at $2,127,000 after acquiring an additional 44,058 shares during the period. State Street Corp boosted its holdings in InMode by 3.7% in the third quarter. State Street Corp now owns 2,044,640 shares of the healthcare company’s stock valued at $34,657,000 after acquiring an additional 73,183 shares during the last quarter. Finally, Atlas Legacy Advisors LLC acquired a new stake in InMode in the fourth quarter worth about $848,000. Institutional investors and hedge funds own 68.04% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on INMD shares. Barclays raised their target price on shares of InMode from $26.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, February 5th. Needham & Company LLC reaffirmed a “hold” rating on shares of InMode in a research note on Tuesday, February 4th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, InMode currently has an average rating of “Hold” and a consensus target price of $22.25.

InMode Trading Up 1.1 %

Shares of INMD opened at $18.63 on Monday. The stock has a market cap of $1.30 billion, a P/E ratio of 7.93 and a beta of 2.08. InMode Ltd. has a 1 year low of $14.87 and a 1 year high of $21.92. The stock’s 50-day moving average price is $18.12 and its two-hundred day moving average price is $17.70.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.